Multiple Myeloma and Amyloidosis Program, Cedars-Sinai | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to Places / Academic & Health Care Centers
Multiple Myeloma And Amyloidosis Program, Cedars-Sinai

Multiple Myeloma and Amyloidosis Program, Cedars-Sinai

8700 Beverly Blvd.
Los Angeles, California, United States
Phone   Web  

The Multiple Myeloma and Amyloidosis program provides a valuable resource to patients with these conditions. They offer a comprehensive array of services and treatment options based on the specific challenges of each patient’s disease characteristics and stage.

Through their various clinical trials, patients with multiple myeloma can access leading-edge, novel therapeutics. The clinical trials are complemented by the program’s basic and translational research in several promising areas, including anti-angiogenesis, vaccines, anti-virus treatments, gene therapy and third-generation bisphosphonates.

Cedars-Sinai is a nonprofit academic healthcare organization serving the diverse Los Angeles community and beyond. With pioneering medical research achievements, education programs defining the future of healthcare, and wide-ranging community benefit activities, they’re setting new standards for quality and innovation in patient care.

The team includes healthcare professionals in the following areas:

Hematology and Oncology:
Robert A. Vescio, MD

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close